KB-0742: A phase 1 and 2 trial of KB-0742 in people with relapsed or refractory non-Hodgkin lymphoma
This trial is testing the medication KB-0742 in adults with non-Hodgkin lymphoma (NHL) which has returned after (relapsed) or not responded (is refractory) to treatment.
You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT04718675
Trial aim and background
The main aim of this trial is to find out our how safe and well tolerated the medication KP-0742 is, and what is the maximum dose that can be used. It also hopes to see how effective it is in patients with NHL which has relapsed or is refractory to treatment.
This is a phase 1 (early phase) trial. Little is known about the safety and effectiveness of this treatment. You might not benefit from the treatment, but the trial will give important information about this new treatment, which could help other people in the future.
Who can enter
People over 18 with NHL which has relapsed after, or become refractory to, other treatments at least 4 weeks ago may be eligible for this trial.
Locations
Recruitment is taking place at the Sarah Cannon Research Institute, London.
Further information
More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT04718675
Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.